[Funding alert] Noord-Brabant-based Biotechnology Company RIBOPRO Secures €1.9M in Funding

Existing investors Vlasroot, BOM, the Fredriks family, and Wietse Mulder, representing EchiumBio Holding BV on the supervisory board, backed the funding round.

Read also -  Zurich-based Payment Fintech Company Rivero Secures €6.3 Million in Series A Round Funding

The infusion of funds will allow the Dutch enterprise to expedite several Research and Development (R&D) endeavours towards particular value tipping points while improving the efficiency of manufacturing procedures.

Sander van Asbeck, CEO of RIBOPRO says, “With this infusion of capital, we specifically aim to deliver proof of concept for our next-generation LNP technology and advance the development of our state-of-the-art mRNA/LNP manufacturing machine, bringing us closer to becoming the go-to provider of mRNA technologies and high quality (GMP) manufacturing. The anticipated breakthrough in mRNA/LNP performance will benefit the hundreds of existing customers, as well as accelerate the acquisition of novel partnerships. We are grateful for the trust and support from our investors, enabling us to grow further into a mature and profitable company and deliver on our mission.”

Roel Elshout, supervisory board member at RIBOPRO and representing Vlasroot, says “We believe in RIBOPRO’s ability to drive meaningful change in the biotech landscape. The innovative mRNA-centric solutions under development by RIBOPRO align with our commitment to supporting groundbreaking technologies that transform the future of healthcare.”

Wietse Mulder, supervisory board member at RIBOPRO and representing EchiumBio says “I am thrilled to be part of RIBOPRO’s journey. The completion of the Convertible Loan Agreement signifies a strong endorsement of the company’s vision and capabilities. We look forward to witnessing the impactful contributions RIBOPRO will make in advancing mRNA research and therapy development.”

The business is dedicated to helping biotech and biopharma develop cutting-edge mRNA therapies based on in-house mRNA technologies and superior mRNA/LNP manufacturing.

Read also - London-based shaka Secures €1 Million in Seed Funding

About RIBOPRO

RIBOPRO is a cutting-edge service provider that produces high-performing, high-quality RNA products that are effective medicines and research instruments.

Read also - Spanish Mobility Company Cabify was Secures €15 Million loan from BBVA Spark

By providing both custom and off-the-shelf RNA products at affordable prices and turnaround times, RiboPro successfully removes all obstacles to the successful use of RNA in our customers' research and development.